Physiological Pacing for the Prevention and Treatment of Heart Failure: a State-of-the-Art Review.
Margaret Infeld, Jamie A Cyr, Damián Sánchez-Quintana...
https://pubmed.ncbi.nlm.nih.gov/39481799/Actively Recruiting
Led by Baylor College of Medicine · Updated on 2025-10-02
2136
Participants Needed
71
Research Sites
N/A
Total Duration
This research aims to compare two pacing methods, His or Left bundle branch pacing HisLBBP and biventricular pacing BiVP, in patients with heart failure caused by left ventricular systolic dysfunction LVEF 50% who have either a wide QRS duration 130 ms or requireanticipate more than 40% pacing. The study focuses on patient-centered outcomes such as quality of life, physical activity, hospitalizations for heart failure, mortality, and device-related complications like lead dislodgement and infection, while participants continue standard heart failure medication. Participants are randomly assigned to receive either HisLBBP or BiVP devices. For patients with LVEF 35%, the HisLBBP group receives a defibrillator with three implanted leads, including a His-bundle or left bundle branch pacing lead, while those with LVEF 36-50% receive a pacemaker with two leads. The BiVP group receives a defibrillator with three leads for LVEF 35% and a pacemaker with three leads, including an epicardial left ventricular lead, for LVEF 36-50%. The pacing devices aim to synchronize heartbeats through different approaches to improve heart function. Throughout the study, participants are monitored for up to 5.5 years. Researchers will assess combined outcomes of all-cause death and heart failure hospitalizations as the primary measure. Secondary assessments include quality of life changes, psychological adjustment at one year, and heart function measured by left ventricular volume changes. Patient activity and heart failure symptoms will also be tracked using questionnaires, walk tests, and implanted device data. Safety and complications related to the devices will be closely followed during the study period.
CONDITIONS
Left vs Left Randomized Clinical Trial
M
Mihail G Chelu, MD, PhD
M
Merin Thomas
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Baylor College of Medicine
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | His/Left Bundle Branch Pacing (His/LBBP) | Biventricular Pacing (BiVP) |
|---|---|---|
| What it is | Implantation of a pacing lead at the His-bundle or left bundle branch region to restore synchronous ventricular activation through the heart’s natural conduction system. | Implantation of a biventricular pacing device with leads to both right and left ventricles to resynchronize electrical activation, with or without a defibrillator depending on ejection fraction. |
| Role in the trial | Experimental pacing method tested as an alternative to standard biventricular pacing. | Established standard-of-care pacing strategy for patients with heart failure and conduction abnormalities. |
| Primary use | Restore rapid and coordinated heart activation by directly engaging the cardiac conduction system in heart failure patients needing pacing. | Deliver resynchronized pacing to both ventricles to improve heart function and clinical outcomes in advanced heart failure with conduction delay. |
| How it is given or performed | Device leads are implanted in the His-bundle or left bundle branch region, with additional right atrial and defibrillator leads as needed based on ejection fraction. | A pacing device is implanted with leads to the right atrium, right ventricle, and an epicardial lead to the left ventricle; device type includes a defibrillator when LVEF is ≤35%. |
| Evidence status | Emerging evidence shows physiological pacing improves electrical synchrony and may offer clinical benefit, but large-scale outcome data remain limited. | Supported by robust evidence as effective for improving outcomes, reducing heart failure hospitalization, and lowering mortality in guideline-eligible patients. |
| Important limitations | Procedural complexity, learning curve for implantation, and less long-term follow-up compared to standard BiVP. Uncertainties remain about optimal patient selection and durability. | Not all patients respond to BiVP, and anatomical or technical challenges can preclude optimal lead placement. Non-responders remain an ongoing clinical concern. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Day of procedure and immediate recovery period
Participants undergo implantation of a device for cardiac resynchronization therapy either using His/Left Bundle Branch Pacing or Biventricular Pacing with a left ventricular epicardial lead.
1 visit (in-person) for device implantation
Duration - Up to 5.5 years
Participants are followed after device implantation to monitor recovery and device function.
Regular follow-up visits as scheduled by the study team
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Margaret Infeld, Jamie A Cyr, Damián Sánchez-Quintana...
https://pubmed.ncbi.nlm.nih.gov/39481799/Temidayo A Abe, Endurance O Evbayekha, Larry R Jackson...
https://pubmed.ncbi.nlm.nih.gov/40250827/Baylor College of Medicine
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor